Basal cell carcinoma

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
Basal cell carcinoma
Classification and external resources
Basal cell carcinoma
ICD-9 173
ICD-O: 8090/3-8093/3
OMIM 605462
DiseasesDB 1264
eMedicine med/214 
MeSH D002280

WikiDoc Resources for

Basal cell carcinoma

Articles

Most recent articles on Basal cell carcinoma

Most cited articles on Basal cell carcinoma

Review articles on Basal cell carcinoma

Articles on Basal cell carcinoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Basal cell carcinoma

Images of Basal cell carcinoma

Photos of Basal cell carcinoma

Podcasts & MP3s on Basal cell carcinoma

Videos on Basal cell carcinoma

Evidence Based Medicine

Cochrane Collaboration on Basal cell carcinoma

Bandolier on Basal cell carcinoma

TRIP on Basal cell carcinoma

Clinical Trials

Ongoing Trials on Basal cell carcinoma at Clinical Trials.gov

Trial results on Basal cell carcinoma

Clinical Trials on Basal cell carcinoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Basal cell carcinoma

NICE Guidance on Basal cell carcinoma

NHS PRODIGY Guidance

FDA on Basal cell carcinoma

CDC on Basal cell carcinoma

Books

Books on Basal cell carcinoma

News

Basal cell carcinoma in the news

Be alerted to news on Basal cell carcinoma

News trends on Basal cell carcinoma

Commentary

Blogs on Basal cell carcinoma

Definitions

Definitions of Basal cell carcinoma

Patient Resources / Community

Patient resources on Basal cell carcinoma

Discussion groups on Basal cell carcinoma

Patient Handouts on Basal cell carcinoma

Directions to Hospitals Treating Basal cell carcinoma

Risk calculators and risk factors for Basal cell carcinoma

Healthcare Provider Resources

Symptoms of Basal cell carcinoma

Causes & Risk Factors for Basal cell carcinoma

Diagnostic studies for Basal cell carcinoma

Treatment of Basal cell carcinoma

Continuing Medical Education (CME)

CME Programs on Basal cell carcinoma

International

Basal cell carcinoma en Espanol

Basal cell carcinoma en Francais

Businness

Basal cell carcinoma in the Marketplace

Patents on Basal cell carcinoma

Experimental / Informatics

List of terms related to Basal cell carcinoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Basal cell carcinoma (BCC) is the most common form of skin cancer. It can be destructive and disfiguring. The risk of developing BCC is increased for individuals with a family history of the disease and with a high cumulative exposure to Ultraviolet light via sunlight or, in the past, were exposed to carcinogenic chemicals especially arsenic. Treatment is with surgery, topical chemotherapy, x-ray, cryosurgery, photodynamic therapy. It is rarely life-threatening but if left untreated can be disfiguring, cause bleeding and produce local destruction (eg., eye, ear, nose, lip).

Forms

Various forms are recognised:

  • Nodular: flesh-colored papule with telangiectasis. If it ulcerates, it becomes a "rodent ulcer" (ulcus rodens), an ulcerating nodule with (often) a pearly border.
  • Cystic: rarer and difficult to distinguish from the nodular form. It has a central cavity with fluid.
  • Pigmented: a variant of the nodular form that may be confused with melanoma.
  • Sclerosing/cicratising: a scar-like lesion.
  • Superficial: a red scaling patch.

About two-thirds of basal cell carcinomas occur on sun-exposed areas of the body. One-third occur on areas of the body that are not exposed to sunlight, emphasizing the genetic susceptibility of the basal cell cancer patients.

Presentation

Basal Cell Carcinomas present as a firm nodule, clearly growing within the skin and below it, rather than on the surface.

Color varies from that of normal skin to dark brown or black, but there is a characteristic "pearly white" translucent quality on the periphery.

Characteristic "rolled edge". Once the basal cells have invaded the deeper tissues the rolled edge disappears.

When BCCs occur at sites other than the face and neck they are usually just red, flat, scaling areas. Thus, superficial BCCs can often be confused with a patch of eczema.

Diagnosis

To diagnose basal cell carcinomas, a biopsy (where tissue is taken for pathological study) is done using local anesthesia. In small lesions, the tumor is generally removed in its entiriety, while larger ones are biopsied first and surgically removed later if it is confirmed that it is malignant.

Histopathology: Basal cell carcinoma is a malignant epithelial tumor arising only in skin, from the basal layer of the epidermis or of the pilosebaceous adnexa. Tumor is represented by compact areas, well delineated and invading the dermis, apparent with no connection with the epidermis. Tumor cells resemble normal basal cells (small, monomorphous) are disposed in palisade at the periphery of the tumor nests, but are spindle-shaped and irregular in the middle. Tumor clusters are separated by a reduced stroma with inflammatory infiltrate. 1

Physical Examination

Ear Nose and Throat

Pathophysiology

Histology of a nodular basal cell carcinoma
Histology of a nodular basal cell carcinoma

Basal cell carcinomas develop in the basal cell layer of the skin. Sunlight exposure leads to the formation of thymine dimers, a form of DNA damage. While DNA repair removes most UV-induced damage, not all crosslinks are excised. There is, therefore, cumulative DNA damage leading to mutations. Apart from the mutagenesis, sunlight depresses the local immune system, possibly decreasing immune surveillance for new tumor cells.

Prevention and early diagnosis

Basal cell carcinoma is the most common skin cancer. It occurs mainly in fair-skinned patients with a family history of this cancer. Sunlight is a factor in about two thirds of these cancers, but one third occur in non sun-exposed areas. Therefore, dermatologists recommend sun screens and annual skin cancer exams to prevent or provide early detection of this common tumor.

Treatment

Most basal cell carcinomas are removed surgically. A common method is "electrodessication and curettage" (ED&C). This is done by scraping the tumor out with a curette and cauterizing the base and margins. The wound is left to heal by itself (secondary intention healing). The cure rate and cosmetic result are excellent, especially in concave areas. It is also the most cost effective treatment. Surgical excision by the dermasurgeon is another option with the margins of excised tissue examined under the microscope. Certain types, like the sclerosing basal cell cancers may need a wider margin, as they develop subtle processes that project outside the visible part of the tumor. Although BCCs are termed carcinomas, they are not invasive cancers - and are therefore not included in national cancer statistics.

Some superficial cancers respond to local therapy with 5-fluorouracil, a chemotherapy agent. Topical treatment with 5% IMIQUIMOD cream (see below also), with 5 applications per week for six weeks has a reported 70 - 90% success rate at reducing, even removing the BCC [basal cell carcinoma]. Imiquimod may be used prior to surgery to reduce the size of the carcinoma. See Chemotherapy. One can expect a great deal of inflammation with this treatment.

Mohs micrographic surgery[3] has the highest cure rate and is especially indicated for recurrent tumors or tumors in areas (eg. eyelid or nose) where minimal amounts of tissue removal are important. Mohs surgery involves checking the base and edges under a microscope before the surgical repair of the site. Specially trained dermasurgeons do this procedure, usually in-office.

A new immune enhancement agent (topical imiquimod, "Aldara") is effective for the treatment of superficial skin cancers (basal cell and squamous cell cancer, and even malignant melanoma in-situ). It is also used pre-operatively to shrink nodular basal cell cancers, thus allowing a smaller surgical excision.

X-ray is still appropriate in older patients who are not candidates for surgery. Cryosurgery is another option, particularly for basal cell cancer invading cartilage, as the healthy cartilage is cryo-resistant.

Treating surgeons (dermasurgeons, plastic surgeons, or other specialists) will recommend one of these modalities as appropriate treatment depending on the tumor size, location, patient age and other variables.

There is also a new treatment using Euphorbia peplus a common garden weed. [4]

Prognosis

Although basal cell carcinoma rarely metastasizes, it grows locally without stopping. The cancer can impinge on vital structures and result in loss extension or loss of function or rarely death. The vast majority of cases can be successfully treated before serious complications occur.

Epidemiology

Basal cell cancer is the most common skin cancer. It is much more common in fair skinned individuals with a family history of basal cell cancer and increases in incidence closer to the equator or at higher altitude. According to Skin Cancer Foundation R[5], there are approximately 800,000[6] new cases yearly in the United States alone.

Most sporadic BCC arise in small numbers on sun-exposed skin of people over age 50, although younger people may also be affected. The development of multiple basal cell cancer at an early age could be indicative of Nevoid basal cell carcinoma syndrome.

References

  1. http://www.ghorayeb.com
  2. http://www.ghorayeb.com
  3. http://www.ghorayeb.com

External links

de:Basaliom

nl:Basaalcelcarcinoomfi:Basaliooma


WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools
In other languages